Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Pharmaceutical Outsourcing Market Size to Surpass US$ 227.8 billion by 2030 – Growth Plus Reports

Published

on

<!– Name:DistributionId Value:8785052 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2790 –> <!– Name:CustomerId Value:1222559 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:eeed8d2c-1ff1-4fa8-8b05-3cf5d09bbb1f –>

Newark, New Castle, USA, March 09, 2023 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global pharmaceutical outsourcing market is expected to clock US$ 227.8 billion by 2030 and to grow at a CAGR of 6.9% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “Pharmaceutical Outsourcing Market – Global Outlook & Forecast 2022-2030”

Request Free Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/pharmaceutical-outsourcing-market/8284

Pharmaceutical Outsourcing Market Scope:

Report Attribute Details
Market size value in 2021 US$ 125.0 billion
Revenue forecast in 2030 US$ 227.8 billion
Growth Rate CAGR of 6.9% from 2022 to 2030
Base year for estimation 2021
Forecast period 2022-2030
Historical Year 2020
Segments covered Services, End User, and Region.
Regional scope North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Market Drivers

The demand for outsourcing services is expected to rise as pharmaceutical companies are seek to reduce costs and improve efficiency fueling the global pharmaceutical outsourcing market’s growth. Pharmaceutical companies are increasingly turning to outsourcing providers with expertise in specific areas such as formulation development, bioanalytical services, and clinical trial data analysis as drug development becomes more complex and specialized.

Furthermore, there is an increasing demand for novel therapeutics to address unmet medical needs. Outsourcing can assist companies in accelerating the development and manufacturing of these new therapies, allowing them to reach the market faster, which is driving the growth of the pharmaceutical outsourcing market.

Digital technologies such as data analytics, artificial intelligence, and machine learning are increasingly being used in the pharmaceutical industry. This is likely to increase demand for outsourcing providers who provide digital services and expertise. Rather than engaging in one-time transactions, many pharmaceutical companies are now seeking long-term strategic partnerships with outsourcing providers. This enables them to gain ongoing access to specialized expertise and resources, as well as collaborate more closely with their partners to achieve their business objectives, thereby fueling the pharmaceutical outsourcing market growth.

Outsourcing can provide access to new markets and expand a company’s global footprint. This can be particularly important for companies looking to enter new regions or expand their existing presence in emerging markets.

The global pharmaceutical outsourcing market is analyzed from three perspectives: Services, End-user, and Region.

Excerpts from ‘By Services Segmentation’

Based on the services, the global pharmaceutical outsourcing market is segmented into:

  • Pharmaceutical Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services

With the highest revenue share in 2021, the biologics manufacturing services segment dominated the pharmaceutical outsourcing market. Biologics manufacturing services are further subdivided into biologics API manufacturing services and biologics FDF manufacturing services. Biologics are a significant and expanding segment of the pharmaceutical industry, with applications in oncology, autoimmune diseases, and infectious diseases. As the demand for biologics grows, so does the demand for specialized expertise and resources in biologics manufacturing. Manufacturing biologics is a complex process that necessitates specialized knowledge and resources, such as advanced technologies, specialized equipment, and highly skilled personnel.

Outsourcing can provide access to resources and expertise that may not be available in-house, increasing the demand for biologics manufacturing outsourcing. Outsourcing biologics manufacturing can also be a cost-effective way for pharmaceutical companies to gain access to specialized expertise and resources while lowering costs and improving efficiency. Biologics manufacturing is highly regulated, with strict quality control, safety, and efficacy requirements. Pharmaceutical companies can ensure regulatory compliance by outsourcing biologics manufacturing to specialized biologics manufacturing service providers.

Excerpts from ‘By End-user Segmentation’

Based on the end-user, the global pharmaceutical outsourcing market is segmented into:

  • Big Pharmaceutical Companies
  • Small & Medium-Sized Pharmaceutical Companies
  • Generic Pharmaceutical Companies

In 2021, big pharmaceutical companies segment had the highest revenue share of the pharmaceutical outsourcing market. Outsourcing can save big pharmaceutical companies money because it avoids the high capital costs of building and maintaining in-house facilities and staff. Big pharmaceutical companies have significant financial resources, allowing them to invest in outsourcing activities on a larger scale than smaller companies, fueling segment growth. Pharmaceutical companies can focus on their core competencies, such as drug discovery and development, by outsourcing other activities to external partners. As a result of the increased efficiency and productivity, large pharmaceutical companies are turning to outsourcing.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/pharmaceutical-outsourcing-market/8284

Excerpts from ‘By Region Segmentation’

Geographically, the global pharmaceutical outsourcing market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

In 2021, North America dominated the market for pharmaceutical outsourcing worldwide. Several of the pharmaceutical firms in the region depend on outsourcing services to compete on the global market. The growth of the pharmaceutical outsourcing business is being aided by North America’s established infrastructure for R&D, manufacturing, and clinical trials. The workforce in North America is highly educated and skilled, enabling it to offer pharmaceutical businesses high-quality services. Furthermore, the region provides a supportive regulatory environment that fosters growth and development in the pharma industry.

Excerpts from ‘Competitive Landscape’

Some prominent players operating in the global Pharmaceutical outsourcing market:

  • Parexel International Corporation
  • The Quantic Group
  • IQVIA
  • Lachman Consultant Services, Inc.
  • GMP Pharmaceuticals Pty Ltd.
  • Concept Heidelberg GmbH
  • Covance Inc.
  • Charles River Laboratories International, Inc.
  • PRA Health Sciences
  • ICON Plc

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL PHARMACEUTICAL OUTSOURCING MARKET – ANALYSIS & FORECAST, BY Services
    1. Pharmaceutical Manufacturing Services
      1. Pharmaceutical API Manufacturing Services
      2. Pharmaceutical FDF Manufacturing Services
    2. Drug Development Services
    3. Biologics Manufacturing Services
      1. Biologics API manufacturing services
      2. Biologics FDF manufacturing services

TOC Continued..

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8284

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse related reports:

Peritoneal Dialysis Market by Product (Devices, Services), Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis), End User (Home-based dialysis, Hospital-based dialysis) – Global Outlook & Forecast 2022-2030

Extracorporeal Membrane Oxygenation (ECMO) Machine Market by Product, (ECMO Machine, Software), Modality (Venoarterial, Venovenous), Patient Type (Neonates, Pediatric Patients), Application (Respiratory, Cardiac, ECPR) – Global Outlook & Forecast 2022-2030

Exosome Diagnostics And Therapeutics Market by Product Type (Kits & Reagents, Instruments), Application (Cancer, Cardiovascular Diseases), End User (Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers) -Global Outlook & Forecast 2022-2030

Bench-top Dental Autoclaves Market by Product (Automatic, Semi-automatic, Manual), by Technology (Pre & Post Vacuum, Gravity), by Class (Class B, Class N, Class S), by End User (Hospitals/Dental Clinics, Dental Laboratories) – Global Outlook & Forecast 2022-2030

Surgical Power Tools Market by Product (Handpiece, Disposables, Accessories), Power source (Electric-operated Power Tools, Battery-driven Power Tools) Application (Orthopedic Surgery, Dental Surgery) – Global Outlook & Forecast 2022-2030

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

ShapeBlue, the CloudStack company, announces a partnership with proIO to deliver private cloud services in Germany, aimed at meeting growing demand in the region

Published

on

shapeblue,-the-cloudstack-company,-announces-a-partnership-with-proio-to-deliver-private-cloud-services-in-germany,-aimed-at-meeting-growing-demand-in-the-region

FRANKFURT, Germany, April 30, 2024 /PRNewswire/ — ShapeBlue, a leader in delivering CloudStack engineering services and support, announces a partnership with proIO, a German Private Cloud Provider empowering SMBs across various industries through its Infrastructure-as-a-Service and Managed Hosting solutions. This collaboration marks a milestone in advancing cloud infrastructure and support for organizations in the region, implementing Apache CloudStack as their IaaS platform.

Both companies recognize the benefits of having control over your cloud infrastructure and having a reliable partner delivering a fully managed IaaS solution. Embracing a managed private cloud environment ensures better cost management and enhances security measures, maximizes hardware investments, ensures flexibility and compliance with regulations. Utilizing CloudStack to orchestrate the IT environment offers companies unparalleled flexibility to tailor their infrastructure to their unique needs while leveraging existing resources effectively.
Giles Sirett, CEO of ShapeBlue commented: “With the partnership with proIO we address the needs of SMBs in Germany for powerful managed cloud. We will focus on adoption of open-source technology, helping them to control costs and ensure reliability.
ShapeBlue has a global footprint, with customers in 19 countries. Driven by the desire of organisations to repatriate cloud workloads and changes in the market, with proIO we aim to repeat the success that we have in other markets.”
proIO and ShapeBlue join forces to help companies in Germany harness the potential of open-source technology backed up by reliable support.
“With our expertise and proven offerings, we will develop innovative solutions and deliver optimal results. We are convinced that this partnership will open up further opportunities and that we can achieve even more together. We look forward to working with ShapeBlue to develop forward-thinking solutions and support our customers in the best possible way.”, says Swen Brüseke, CEO at proIO.
This new partnership allows German companies to benefit from the local presence of proIO, their experience as a CloudStack integrator and ShapeBlue’s 100s of man-years of experience in designing and building complex cloud, network, and storage infrastructure with Apache CloudStack.
proIO
proIO is a Private Cloud Provider empowering German SMBs through its Infrastructure-as-a-Service and Managed Hosting solutions, based in Frankfurt, Germany.
ShapeBlue
ShapeBlue is the largest independent integrator of CloudStack technologies globally and specialists in designing and implementing IaaS cloud infrastructures for private and public cloud implementations.

View original content:https://www.prnewswire.co.uk/news-releases/shapeblue-the-cloudstack-company-announces-a-partnership-with-proio-to-deliver-private-cloud-services-in-germany-aimed-at-meeting-growing-demand-in-the-region-302128774.html

Continue Reading

Artificial Intelligence

Implantica Announces Real-World Clinical Data from over 200 Patients treated across five RefluxStop™ Centers in Europe Presented at SAGES in Cleveland

Published

on

implantica-announces-real-world-clinical-data-from-over-200-patients-treated-across-five-refluxstop™-centers-in-europe-presented-at-sages-in-cleveland

VADUZ, Liechtenstein, April 30, 2024 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports many presentations including new RefluxStop™ real-world data from over 200 patients at five hospitals across Europe, were presented in Scientific Sessions at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Scientific Meeting.

This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery. Some 2,500 SAGES members, representing the world-leading experts in gastrointestinal and endoscopic surgery, attended the SAGES Annual Meeting in Cleveland, Ohio on April 17-20.
It’s a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES. The Centers of Excellence included the following:
Krankenhaus Nordwest GmbH, Frankfurt, Germany Presenting author: Dr. Moustafa ElshafeiHirslanden Beau-Site Hospital, Bern, Switzerland Presenting author: Dr. Joerg ZehetnerInselspital, University Hospital, Bern, Switzerland Presenting author: Dr. Yves BorbélyAKH University Hospital Vienna, AustriaPresenting author: Prof. Dr. Sebastian SchoppmannClinics for General and Visceral Surgery, Klinikum Friedrichshafen, GermanyPresenting author: Dr. Thortsen G. LehmannDr. Peter Forsell, CEO of Implantica says, “The excellent real-world outcomes from a dataset that is four times bigger than the size of the CE study conducted more than five years ago is a strong validation of the consistent and sustained outcomes of the RefluxStop therapy. This research further establishes RefluxStop™ as an exceptional surgical treatment for GERD, setting the stage for strong future growth in US once we get market approval.”
Dr. Forsell goes on to say, “There has been an immense interest and support in RefluxStop™ therapy from the US surgeons and scientific experts. Looking to the US market where 20% of the adult population suffers from GERD1, we see a massive opportunity for the innovative RefluxStop™ procedure to transform patients’ quality of life, pending FDA approval.”
Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017 Feb;10(2):243-251. doi: 10.1177/1756283X16681701. Epub 2017 Jan 5. PMID: 28203282; PMCID: PMC5298478.For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 [email protected]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company’s Certified Adviser is FNCA Sweden AB, [email protected]
The information was sent for publication, through the agency of the contact person set out above, on April 30, 2024, at 08:00 a.m. (CET).
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
About RefluxStop™
RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It’s unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter’s closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.
In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position.
The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.
Newsroomhttps://www.implantica.com/media/media-kit
Communityhttps://ch.linkedin.com/company/implanticahttps://www.twitter.com/implantica
Media Contact:Juanita Eberhart, VP Marketing & AdvocacyM: +1 [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-announces-real-world-clinical-data-from-over-200-patients-treated-across-five-refluxstop-,c3970435
The following files are available for download:
https://mb.cision.com/Main/19732/3970435/2769366.pdf
Implantica Announces Real-World Clinical Data from over 200 Patients treated across five RefluxStop™ Centers in Europe Presented at SAGES in Cleveland
 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-announces-real-world-clinical-data-from-over-200-patients-treated-across-five-refluxstop-centers-in-europe-presented-at-sages-in-cleveland-302131141.html

Continue Reading

Artificial Intelligence

Inspira Enterprise Named a Leader in the 2024 IDC MarketScape Report for Worldwide Emerging MDR Services

Published

on

inspira-enterprise-named-a-leader-in-the-2024-idc-marketscape-report-for-worldwide-emerging-mdr-services

DALLAS, April 30, 2024 /PRNewswire/ — Inspira Enterprise, Inc. (‘Inspira’), a global cybersecurity services organization is proud to announce that it has been positioned in the Leaders category in the 2024 IDC MarketScape Report for worldwide emerging managed detection and response (MDR) services.

In the assessment conducted by IDC for its MarketScape, vendors were meticulously scrutinized against a comprehensive array of benchmarks encompassing, functionality, offerings, security outcomes, go-to-market strategy, customer portal, talent management, service tiers, range of services, future outlook, security outcome, and cost normalization. IDC’s discerning evaluation heralded Inspira’s proactive detection and closed-loop remediation, as the integral components of its cutting-edge Intelligence-Driven Cyber Defense (ICD) practice.  
According to the IDC MarketScape Report, “MDR services have experienced significant growth, fueled by the escalating sophistication and frequency of cyber threats. Organizations are increasingly turning to MDR services as the cornerstone of fortifying their digital fortresses against the relentless tide of evolving cyber threats. to enhance their overall cybersecurity posture. This strategic shift underscores a profound recognition of the imperative to not merely respond reactively but to proactively anticipate and neutralize emerging risks with unparalleled agility and efficacy.” 
Commenting on Inspira’s strengths, Yogesh Shivhare, Research Manager, Security & Infrastructure, at IDC Canada stated, “Inspira Enterprise’s MDR offering extends beyond threat containment to include a closed-loop remediation process. After containment, this process ensures that enterprise-wide policies and configurations are updated, effectively preventing future attacks using similar methods. This process enables Inspira’s service to improve analyst interaction and develop a deeper understanding of the client’s context.” He also added, “Inspira Enterprise brings a wealth of experience in providing threat detection and response services in complex environments, particularly for midmarket and enterprise clients in the banking and financial services (BFSI), healthcare and life sciences (HCLS), and public sector, with steady adoption of its services within organizations in other industry verticals.”
Inspira’s visionary approach is epitomized by its formidable arsenal of accelerators which forms the foundation for assisting its clientele to transition from their incumbent security information and event management solutions to Inspira’s state-of-the-art MDR platform. Automation and orchestration are foundational to Inspira’s MDR service, with over 130+ playbooks facilitating a 15-minute detection, 30-minute containment, and 4-hour remediation SLA for highest severity incidents.
“Our team is indeed honored to be recognized by IDC MarketScape as a Leader for Worldwide MDR Services,” said Chetan Jain, Managing Director, of Inspira Enterprise. “This acknowledgment is a validation of our commitment to safeguard our clients’ digital assets. We tailor our MDR services to the business context, by integrating SIEM, UEBA, SOAR, and TIP capabilities while also delivering a unified cyber-risk dashboard to provide visibility into threat detection coverage and maturity. We cater to midsize to large clients with complex IT environments who are looking to completely outsource cyber defense or augment their existing SOC efforts.”
Inspira Enterprise has invested significantly in developing its native MDR platform, (iMDR), expected to be available to clients in 2024. This platform will bring advanced detection and hunting capabilities along with a GenAI-enabled dashboard embedded in its iSMART2 customer portal. Inspira Enterprise is also diversifying its services with offerings like deception as a service, IT-OT converged SOC, and continues to invest in service offerings and automation to improve SOC Program Governance through measurable and actionable KPIs. Inspira Enterprise’s proactive stance and ongoing investments position it as a forward-thinking partner in the dynamic field of managed detection and response services.
Read more: https://inspiraenterprise.com/ugiltecm/2024/04/IDC-MarketScape-Worldwide-Emerging-Managed-Detection-and-Response-Services-2024-Vendor-Assessment-2024-Apr.pdf
About Inspira
Inspira Enterprise is a global Cybersecurity, Data Analytics, and AI services provider with a presence in North America, ASEAN, the Middle East, India, and Africa regions. It offers a wide range of services for Banking, Financial Services and Insurance (BFSI), Healthcare, Public Sector, Manufacturing, Information Technology Enabled Services (ITeS), eCommerce, and others. Inspira’s cybersecurity services range from basic perimeter security to complex incident management and response and managed security services. The organization’s global partnerships with best-of-breed technology providers enable it to offer cutting-edge cybersecurity solutions. Inspira’s Managed Analytics service supports its customer’s IT and Business teams, to bridge data strategies with business outcomes. 
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
Media Contact:
[email protected]+91 2240569999
Logo: https://mma.prnewswire.com/media/2400111/Inspira_Enterprise_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/inspira-enterprise-named-a-leader-in-the-2024-idc-marketscape-report-for-worldwide-emerging-mdr-services-302130176.html

Continue Reading

Trending